Chronic Rhinosinusitis (Diagnosis) Clinical Trial
Official title:
Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis - a Randomized, Double Blind, Placebo Controlled Trial
The hypothesis of this study is that a gastroesophageal reflux recommended treatment with proton pump inhibitor (dose and duration) compared to placebo significantly reduces both the signs and symptoms of laryngopharyngeal reflux and comorbid chronic rhinosinusitis. Primary objective was to determine whether 8 weeks of treatment with omeprazole 20 mg ones daily (OD) significantly reduces the signs and symptoms of laryngopharyngeal reflux when compared to placebo in patients with laryngopharyngeal reflux with comorbid chronic rhinosinusitis. Secondary objectives were to determine whether 8 weeks of treatment with omeprazole 20 mg OD significantly reduces the signs and symptoms of comorbid chronic rhinosinusitis in patients with laryngopharyngeal reflux when compared to matching placebo; and to investigate the association of the severity of signs and symptoms of laryngopharyngeal reflux with the ones of chronic rhinosinusitis in the same group of patients. The research was carried out as a double blind randomized placebo controlled trial. Patients were randomized into two groups in an approximate 1:1 ratio using a concealed random sequence. After randomization and initial assessment treatment was initialized. Patients on active treatment were given omeprazole 20 mg once daily half an hour before breakfast for 8 weeks, while those in the placebo group were given matching placebo tablets using the same regimen for 8 weeks as the group on the active treatment. Patients were reassessed at the end of treatment for signs and symptoms of laryngopharyngeal reflux and comorbid chronic rhinosinusitis.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05895929 -
The Role of IL5 in Epithelial Cell Integrity
|
Early Phase 1 | |
Completed |
NCT03673956 -
Topical Antibiotics in Chronic Rhinosinusitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT03970655 -
Functional Endoscopic Sinus Surgery Study
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04514120 -
Alsaleh-Javer Endoscopic Sinus Score (AJESS) System
|
N/A | |
Recruiting |
NCT03963648 -
NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP
|
N/A | |
Recruiting |
NCT05009758 -
Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps
|
N/A | |
Active, not recruiting |
NCT05553951 -
Adherence in Global Airways
|
N/A | |
Completed |
NCT03563521 -
Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma
|
||
Completed |
NCT05035654 -
LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)
|
Phase 2 | |
Withdrawn |
NCT03369574 -
Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab
|
||
Recruiting |
NCT05400616 -
Nasal Microbiota Transfer Therapy in Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
N/A | |
Recruiting |
NCT04628442 -
Tissue Immune Interaction in Nasal Polyposis
|
||
Completed |
NCT04041609 -
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)
|
Phase 2 | |
Completed |
NCT04048070 -
The Effect of Enhanced Recovery After Surgery in Endoscopic Sinus Surgery
|
N/A | |
Recruiting |
NCT03439865 -
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis
|
Early Phase 1 | |
Recruiting |
NCT05857228 -
Viral and Epigenetic Influences in CRSwNP
|
||
Completed |
NCT03122795 -
Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
|
N/A | |
Recruiting |
NCT05295459 -
Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
|
Phase 3 | |
Completed |
NCT04858802 -
A Clinical Evaluation of PROPEL® Contour Sinus Implant
|
N/A | |
Completed |
NCT04572516 -
Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis
|
Phase 3 |